Sec Form 4/A Filing - Knight Therapeutics (Barbados) Inc. @ Synergy CHC Corp. - 2016-12-22

FORM 4/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Knight Therapeutics (Barbados) Inc. 2. Issuer Name and Ticker or Trading Symbol Synergy CHC Corp. [ SNYR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) THE BUSINESS CENTER, UPTON 3. Date of Earliest Transaction (MM/DD/YY) 12/22/2016 (Street) ST. MICHAEL, C8BB11103 4. If Amendment, Date Original Filed (MM/DD/YY) 11/16/2015 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/22/2016 J( 1 ) 7,500,000 A 17,645,812 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants $ 0.34 12/22/2016 J( 1 ) 1 01/22/2015 01/22/2025 Common Shares 3,584,759 ( 1 ) 0 D Warrants $ 0.49 12/22/2016 J( 1 ) 1 11/12/2015 11/12/2025 Common Shares 4,547,243 ( 1 ) 0 D Stock Options $ 0.25 12/22/2016 J( 1 ) 1 12/14/2015 12/14/2025 Common Shares 1,000,000 ( 1 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Knight Therapeutics (Barbados) Inc. THE BUSINESS CENTER, UPTON ST. MICHAEL, C8BB11103 X Signatures /s/ Michel Loustric 12/23/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.